Pharmacoepidemiology and Pharmacovigilance in Drug Therapy: New Issues, Challenges, and Applications
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 November 2024 | Viewed by 113
Special Issue Editor
Special Issue Information
Dear Colleagues,
Pharmacoepidemiology and pharmacovigilance are critical disciplines that serve to optimize drug therapy and ensure patient safety through monitoring and evaluating the effects of drugs used across large populations. These fields face evolving challenges and new issues as the pharmaceutical landscape becomes increasingly complex and globalized. Adverse drug reactions (ADRs) and medication errors are a significant health burden, emphasizing the need for robust pharmacovigilance systems in order to mitigate these risks effectively. The challenges are manifold, including the integration of vast amounts of data from electronic health records, patient registries, and other sources, which require sophisticated analytical tools to yield actionable insights. Moreover, the globalization of pharmaceutical markets demands harmonized regulatory frameworks to manage drug safety effectively across different regions with varying health policies. Recent advancements in data analytics, artificial intelligence, and machine learning have revolutionized these fields, enhancing the ability to detect, analyze, and prevent medication-related issues. These technologies facilitate the identification of patterns that might elude traditional analysis, offering the potential to preemptively address safety concerns before they pose significant risks to patients.
In this Special Issue, we are excited to bring together leading research that not only addresses these challenges, but also highlights innovative strategies and tools that are pushing the boundaries of what pharmacoepidemiology and pharmacovigilance can achieve. We aim to explore cutting-edge approaches in drug safety monitoring, regulatory practices, and the application of new technologies that promise to enhance the effectiveness and safety of drug therapies.
This Issue is dedicated to showcasing the latest developments and fostering a dialogue that will propel pharmacoepidemiology and pharmacovigilance into a new era of drug safety and efficacy.
Dr. Loreta Kubilienė
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacoepidemiology
- pharmacovigilance
- drug safety monitoring
- regulatory practices
- hospitalization
- adverse drug events
- drug safety
- preventability
